Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia

FEBS Letters

Volumn 583, Issue 15, 2009, Pages 2565-2572

  Wootla, Bharath ^a,b,c,d   Mahendra, Ankit ^a,b,c,d   Dimitrov, Jordan D ^a,b,c   Friboulet, Alain ^d   Borel Derlon, Annie ^e   Rao, Desirazu N ^f   Uda, Taizo ^g   Borg, Jeanne Yvonne ^h   Bayry, Jagadeesh ^a,b,c   Kaveri, Srinivas V ^a,b,c   Lacroix Desmazes, Sébastien ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^e UNIVERSITÉ DE CAEN   (France)

^f INDIAN INSTITUTE OF SCIENCE   (India)

^g OITA UNIVERSITY   (Japan)

^h ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Acquired hemophilia; Catalytic antibody; Factor VIII; FVIII inhibitor; Hemophilia A; PFR MCA

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CORTICOSTEROID; COUMARIN DERIVATIVE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADULT; AGED; ALLOIMMUNITY; ARTICLE; AUTOIMMUNITY; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; MALE; MIDDLE AGED;

EID: 67849097023     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.07.009     Document Type: Article

References (22)

1. Kessler C.M. Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future. Haematologica 85 (2000) 57-61 discussion 61-63
2. Ma A.D., and Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematol. Am. Soc. Hematol. Educ. Program 432 (2006) 7
3. Fulcher C.A., de Graaf Mahoney S., and Zimmerman T.S. Factor VIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 69 5 (1987) 1475-1480
4. Scandella D., Nakai H., Felch M., Mondorf W., Scharrer I., Hoyer L., and Saenko E. In hemophilia and autoantibody inhibitor patients: the factor VIII a2 domain and light chain are most immunogenic. Thromb. Res. 101 (2001) 377-385
5. Shapiro S. The immunologic character of acquired inhibitors of antihemophiliac globulin (factor VIII) and the kinetics of their interaction with FVIII. J. Clin. Invest. 46 (1967) 147-156
6. Lacroix-Desmazes S., et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat. Med. 5 (1999) 1044-1047
7. Wootla B., et al. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J. Immunol. 180 (2008) 7714-7720
8. Lacroix-Desmazes S., et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N. Engl. J. Med. 346 (2002) 662-667
9. Lacroix-Desmazes S., et al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J. Immunol. 177 (2006) 1355-1363
10. Fulcher C.A., Lechner K., and de Graaf Mahoney S. Immunoblot analysis shows changes in FVIII inhibitor chain specificity in FVIII inhibitor patients over time. Blood 72 (1988) 1348-1356
11. Lacroix-Desmazes S., Moreau A., Pashov A., Sooryanarayana S.D., Saint-Remy J.M., Kaveri S.V., and Kazatchkine M.D. Natural antibodies to factor VIII. Semin. Thromb. Hemost. 26 (2000) 157-165
12. Hu G., Guo D., Key N.S., and Conti-Fine B.M. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb. Haemost. 97 (2007) 788-794
13. Gao Q.S., Sun M., Tyutyulkova S., Webster D., Rees A., Tramontano A., Massey R.J., and Paul S. Molecular cloning of a proteolytic antibody light chain. J. Biol. Chem. 269 (1994) 32389-32393
14. Li L., Paul S., Tyutyulkova S., Kazatchkine M.D., and Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J. Immunol. 154 (1995) 3328-3332
15. Paul S., et al. Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease. J. Immunol. 159 (1997) 1530-1536
16. Kalaga R., Li L., O'Dell J.R., and Paul S. Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. J. Immunol. 155 (1995) 2695-2702
17. Lacroix-Desmazes S., et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc. Natl. Acad. Sci. USA 102 (2005) 4109-4113
18. Wootla B., et al. Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. J. Immunol. 180 (2008) 8455-8460
19. Aird W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101 (2003) 3765-3777
20. Holschermann H., et al. Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts. Circulation 102 (2000) 357-363
21. Holschermann H., et al. In situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy. Am. J. Pathol. 154 (1999) 211-220
22. Yen M.H., Pilkington G., Starling R.C., Ratliff N.B., McCarthy P.M., Young J.B., Chisolm G.M., and Penn M.S. Increased tissue factor expression predicts development of cardiac allograft vasculopathy. Circulation 106 (2002) 1379-1383